NovMetaPharma Co (XKRX:229500) Other Income (Expense) : ₩-158.85 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Other Income (Expense)?

NovMetaPharma Co's other income expense for the NovMetaPharma Co's pretax income for the six months ended in Dec. 2024 was ₩-158.85 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-158.85 Mil.

NovMetaPharma Co Other Income (Expense) Historical Data

The historical data trend for NovMetaPharma Co's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Other Income (Expense) Chart

NovMetaPharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

-164.38

-519.44

1,668.23

-4,673.86

-158.85

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Other Income (Expense)	Get a 7-Day Free Trial					-164.38	-519.44	1,668.23	-4,673.86	-158.85

NovMetaPharma Co Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-158.85 Mil.

NovMetaPharma Co (XKRX:229500) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

NovMetaPharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Other Income (Expense)

Traded in Other Exchanges

N/A

Address

727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR

Website

http://www.novmeta.com

NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines